Experience

Davis Polk advised the dealers of a senior unsecured Rule 144A/Regulation S offering by Crédit Agricole S.A. (“Crédit Agricole”), as issuer, acting through its London branch, of series no…

Davis Polk advised Markit Ltd. in connection with its SEC-registered secondary offering of 27,501,271 common shares sold by 15 selling shareholders, including 1,754,667 shares sold upon the…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Mohawk Industries, Inc. of €500 million aggregate principal amount of 2.000% senior notes due 2022.  …

Davis Polk advised the managers of the Rule 144A/Regulation S offering by NXP B.V. and NXP Funding LLC of $600 million principal amount of 4.125% senior notes due 2020 and $400 million…

Davis Polk advised the global coordinators in connection with a Rule 144A/Regulation S offering of $1.6 billion aggregate principal amount of 6.50% senior notes due 2022 by XPO Logistics,…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by TTX Company of $300 million aggregate principal amount of its 2.6%…

Davis Polk advised the joint book-running managers in connection with a $750 million SEC-registered offering by Autodesk, Inc., consisting of $450 million aggregate principal amount of 3…

Davis Polk advised the initial purchasers in connection with the Rule 144A/Regulation S offering by the Government of the Democratic Socialist Republic of Sri Lanka of US$650 million…

We successfully resolved several disputes on behalf of the wind energy company

Davis Polk is advising Bio-Reference Laboratories, Inc. in connection with its approximately $1.47 billion acquisition by OPKO Health, Inc. Under the terms of the agreement, holders of Bio…